Skip to main content
Top
Published in: Endocrine 3/2012

01-06-2012 | Original Article

Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas

Authors: Junna Ye, Yan Qi, Weiqing Wang, Fukang Sun, Qin Wei, Tingwei Su, Weiwei Zhou, Yiran Jiang, Wenqi Yuan, Jianfei Cai, Bin Cui, Guang Ning

Published in: Endocrine | Issue 3/2012

Login to get access

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy accounting for approximately 0.02–0.2% of all cancer deaths. The molecular pathogenesis of ACC has been the hot topic of recent reviews but it is still poorly understood. It is imperative to have a better understanding on the pathophysiology of ACC so as to establish precise diagnosis and effective treatment. This study aims to identify the molecular markers between ACCs and adrenocortical adenomas (ACAs). With MLPA, we checked on 10 ACA and 9 ACC tissue samples. The MLPA results showed deletion on chromosomes 18q, 11q, 11p, and 13q and duplication on chromosomes 3q, 4q, 6p, and 19p. There was a significant difference in the number of aberration copies of the ataxia telangiectasia-mutated (ATM) gene located on chromosome 11q22–q23 between ACCs and ACAs. Five out of 9 (56%) ACC specimens had deletion of ATM (P = 0.011). RT-PCR result then demonstrated that ATM mRNA level is lower in ACCs than in ACAs (P < 0.001). In addition, immunohistochemistry (IHC) study of the 19 ACA and 18 ACC samples confirmed lower expression of ATM protein in ACCs than in ACAs (P < 0.001). The study demonstrated that ATM expression was diminished in ACC than in ACA, suggesting an important role of ATM in the tumorigenesis of ACC.
Literature
1.
go back to reference E.A. Stephan, T.H. Chung, C.S. Grant, S. Kim, D.D. Von Hoff, J.M. Trent, M.J. Demeure, Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther. 7, 425–431 (2008)PubMedCrossRef E.A. Stephan, T.H. Chung, C.S. Grant, S. Kim, D.D. Von Hoff, J.M. Trent, M.J. Demeure, Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther. 7, 425–431 (2008)PubMedCrossRef
2.
go back to reference B.L. Wajchenberg, M.A. Albergaria Pereira, B.B. Medonca, A.C. Latronico, P. Campos Carneiro, V.A. Alves, M.C. Zerbini, B. Liberman, G. Carlos Gomes, M.A. Kirschner, Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88, 711–736 (2000)PubMedCrossRef B.L. Wajchenberg, M.A. Albergaria Pereira, B.B. Medonca, A.C. Latronico, P. Campos Carneiro, V.A. Alves, M.C. Zerbini, B. Liberman, G. Carlos Gomes, M.A. Kirschner, Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88, 711–736 (2000)PubMedCrossRef
3.
go back to reference B. Allolio, S. Hahner, D. Weismann, M. Fassnacht, Management of adrenocortical carcinoma. Clin. Endocrinol. 60, 273–287 (2004)CrossRef B. Allolio, S. Hahner, D. Weismann, M. Fassnacht, Management of adrenocortical carcinoma. Clin. Endocrinol. 60, 273–287 (2004)CrossRef
4.
go back to reference C.A. Koch, K. Pacak, G.P. Chrousos, The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J. Clin. Endocrinol. Metab. 87, 5367–5384 (2002)PubMedCrossRef C.A. Koch, K. Pacak, G.P. Chrousos, The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J. Clin. Endocrinol. Metab. 87, 5367–5384 (2002)PubMedCrossRef
5.
go back to reference J.F. Bremmer, B.J. Braakhuis, H.J. Ruijter-Schippers, A. Brink, H.M. Duarte, D.J. Kuik, E. Bloemena, C.R. Leemans, I. van der Waal, R.H. Brakenhoff, A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab. Invest. 85, 1481–1488 (2005)PubMed J.F. Bremmer, B.J. Braakhuis, H.J. Ruijter-Schippers, A. Brink, H.M. Duarte, D.J. Kuik, E. Bloemena, C.R. Leemans, I. van der Waal, R.H. Brakenhoff, A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab. Invest. 85, 1481–1488 (2005)PubMed
6.
go back to reference S. Sidhu, M. Sywak, B. Robinson, L. Delbridge, Adrenocortical cancer: recent clinical and molecular advances. Curr. Opin. Oncol. 16, 13–18 (2004)PubMedCrossRef S. Sidhu, M. Sywak, B. Robinson, L. Delbridge, Adrenocortical cancer: recent clinical and molecular advances. Curr. Opin. Oncol. 16, 13–18 (2004)PubMedCrossRef
7.
go back to reference R. Libé, J. Bertherat, Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur. J. Endocrinol. 153, 477–487 (2005)PubMedCrossRef R. Libé, J. Bertherat, Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur. J. Endocrinol. 153, 477–487 (2005)PubMedCrossRef
8.
go back to reference M. Dohna, M. Reincke, A. Mincheva, B. Allolio, S. Solinas-Toldo, P. Lichter, Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28, 145–152 (2000)PubMedCrossRef M. Dohna, M. Reincke, A. Mincheva, B. Allolio, S. Solinas-Toldo, P. Lichter, Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28, 145–152 (2000)PubMedCrossRef
9.
go back to reference F.B. Hogervorst, P.M. Nederlof, J.J. Gille, C.J. McElgunn, M. Grippeling, R. Pruntel, R. Regnerus, T. van Welsem, R. van Spaendonk, F.H. Menko, I. Kluijt, C. Dommering, S. Verhoef, J.P. Schouten, L.J. van’t Veer, G. Pals, Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 63, 1449–1453 (2003)PubMed F.B. Hogervorst, P.M. Nederlof, J.J. Gille, C.J. McElgunn, M. Grippeling, R. Pruntel, R. Regnerus, T. van Welsem, R. van Spaendonk, F.H. Menko, I. Kluijt, C. Dommering, S. Verhoef, J.P. Schouten, L.J. van’t Veer, G. Pals, Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 63, 1449–1453 (2003)PubMed
10.
go back to reference M.C. van Dijk, P.D. Rombout, S.H. Boots-Sprenger, H. Straatman, M.R. Bernsen, D.J. Ruiter, J.W. Jeuken, Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn. Mol. Pathol. 14, 9–16 (2005)PubMedCrossRef M.C. van Dijk, P.D. Rombout, S.H. Boots-Sprenger, H. Straatman, M.R. Bernsen, D.J. Ruiter, J.W. Jeuken, Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn. Mol. Pathol. 14, 9–16 (2005)PubMedCrossRef
11.
go back to reference C. Postma, M.A. Hermsen, J. Coffa, J.P. Baak, J.D. Mueller, E. Mueller, B. Bethke, J.P. Schouten, M. Stolte, G.A. Meijer, Chromosomal instability in flat adenomas and carcinomas of the colon. J. Pathol. 205, 514–521 (2005)PubMedCrossRef C. Postma, M.A. Hermsen, J. Coffa, J.P. Baak, J.D. Mueller, E. Mueller, B. Bethke, J.P. Schouten, M. Stolte, G.A. Meijer, Chromosomal instability in flat adenomas and carcinomas of the colon. J. Pathol. 205, 514–521 (2005)PubMedCrossRef
12.
go back to reference M. Fassnacht, S. Johanssen, M. Quinkler, P. Bucsky, H.S. Willenberg, F. Beuschlein, M. Terzolo, H.H. Mueller, S. Hahner, B. Allolio, Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009)PubMedCrossRef M. Fassnacht, S. Johanssen, M. Quinkler, P. Bucsky, H.S. Willenberg, F. Beuschlein, M. Terzolo, H.H. Mueller, S. Hahner, B. Allolio, Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009)PubMedCrossRef
13.
go back to reference L.M. Weiss, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 8, 163–169 (1984)PubMedCrossRef L.M. Weiss, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 8, 163–169 (1984)PubMedCrossRef
14.
go back to reference L.M. Weiss, L.J. Medeiros Jr, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989)PubMedCrossRef L.M. Weiss, L.J. Medeiros Jr, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989)PubMedCrossRef
15.
go back to reference F.P. Li Jr, J.F. Fraumeni, Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747–752 (1969)PubMed F.P. Li Jr, J.F. Fraumeni, Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747–752 (1969)PubMed
16.
go back to reference H. Ohgaki, P. Kleihues, P.U. Heitz, p53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 54, 408–410 (1993)PubMedCrossRef H. Ohgaki, P. Kleihues, P.U. Heitz, p53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 54, 408–410 (1993)PubMedCrossRef
17.
go back to reference S.R. Lin, Y.J. Lee, J.H. Tsai, Mutations of the p53 gene in human functional adrenal neoplasms. J. Clin. Endocrinol. Metab. 78, 483–491 (1994)PubMedCrossRef S.R. Lin, Y.J. Lee, J.H. Tsai, Mutations of the p53 gene in human functional adrenal neoplasms. J. Clin. Endocrinol. Metab. 78, 483–491 (1994)PubMedCrossRef
18.
go back to reference M. Reincke, C. Wachenfeld, P. Mora, A. Thumser, C. Jaursch-Hancke, S. Abdelhamid, G.P. Chrousos, B. Allolio, p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 “hot spot” found in Taiwan. J. Clin. Endocrinol. Metab. 81, 3636–3638 (1996)PubMedCrossRef M. Reincke, C. Wachenfeld, P. Mora, A. Thumser, C. Jaursch-Hancke, S. Abdelhamid, G.P. Chrousos, B. Allolio, p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 “hot spot” found in Taiwan. J. Clin. Endocrinol. Metab. 81, 3636–3638 (1996)PubMedCrossRef
19.
go back to reference M. Li, J.A. Squire, R. Weksberg, Molecular genetics of Wiedemann–Beckwith syndrome. Am. J. Med. Genet. 79, 253–259 (1998)PubMedCrossRef M. Li, J.A. Squire, R. Weksberg, Molecular genetics of Wiedemann–Beckwith syndrome. Am. J. Med. Genet. 79, 253–259 (1998)PubMedCrossRef
20.
go back to reference V. Ilvesmaki, A.I. Kahri, P.J. Miettinen, R. Voutilainen, Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 77, 852–858 (1993)PubMedCrossRef V. Ilvesmaki, A.I. Kahri, P.J. Miettinen, R. Voutilainen, Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 77, 852–858 (1993)PubMedCrossRef
21.
go back to reference C. Gicquel, X. Bertagna, H. Schneid, M. Francillard-Leblond, J.P. Luton, F. Girard, Y. Le Bouc, Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 78, 1444–1453 (1994)PubMedCrossRef C. Gicquel, X. Bertagna, H. Schneid, M. Francillard-Leblond, J.P. Luton, F. Girard, Y. Le Bouc, Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 78, 1444–1453 (1994)PubMedCrossRef
22.
go back to reference D.S. Tan, C. Marchiò, J.S. Reis-Filho, Hereditary breast cancer: from molecular pathology to tailored therapies. J. Clin. Pathol. 61, 1073–1082 (2008)PubMedCrossRef D.S. Tan, C. Marchiò, J.S. Reis-Filho, Hereditary breast cancer: from molecular pathology to tailored therapies. J. Clin. Pathol. 61, 1073–1082 (2008)PubMedCrossRef
23.
go back to reference M.B. Kastan, D.S. Lim, The many substrates and functions of ATM. Natl. Rev. Mol. Cell Biol. 1, 179–186 (2000)CrossRef M.B. Kastan, D.S. Lim, The many substrates and functions of ATM. Natl. Rev. Mol. Cell Biol. 1, 179–186 (2000)CrossRef
24.
go back to reference K. Savitsky, S. Sfez, D.A. Tagle, Y. Ziv, A. Sartiel, F.S. Collins, Y. Shiloh, G. Rotman, The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4, 2025–2032 (1995)PubMedCrossRef K. Savitsky, S. Sfez, D.A. Tagle, Y. Ziv, A. Sartiel, F.S. Collins, Y. Shiloh, G. Rotman, The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4, 2025–2032 (1995)PubMedCrossRef
25.
go back to reference K. Savitsky, A. Bar-Shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, D.A. Tagle, S. Smith, T. Uziel, S. Sfez, M. Ashkenazi, I. Pecker, M. Frydman, R. Harnik, S.R. Patanjali, A. Simmons, G.A. Clines, A. Sartiel, R.A. Gatti, L. Chessa, O. Sanal, M.F. Lavin, N.G. Jaspers, A.M. Taylor, C.F. Arlett, T. Miki, S.M. Weissman, M. Lovett, F.S. Collins, Y. Shiloh, A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749–1753 (1995)PubMedCrossRef K. Savitsky, A. Bar-Shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, D.A. Tagle, S. Smith, T. Uziel, S. Sfez, M. Ashkenazi, I. Pecker, M. Frydman, R. Harnik, S.R. Patanjali, A. Simmons, G.A. Clines, A. Sartiel, R.A. Gatti, L. Chessa, O. Sanal, M.F. Lavin, N.G. Jaspers, A.M. Taylor, C.F. Arlett, T. Miki, S.M. Weissman, M. Lovett, F.S. Collins, Y. Shiloh, A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749–1753 (1995)PubMedCrossRef
26.
go back to reference M. Platzer, G. Rotman, D. Bauer, T. Uziel, K. Savitsky, A. Bar-Shira, S. Gilad, Y. Shiloh, A. Rosenthal, Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire ATM gene. Genome Res. 7, 592–605 (1997)PubMed M. Platzer, G. Rotman, D. Bauer, T. Uziel, K. Savitsky, A. Bar-Shira, S. Gilad, Y. Shiloh, A. Rosenthal, Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire ATM gene. Genome Res. 7, 592–605 (1997)PubMed
27.
go back to reference J.P. Reddy, S. Peddibhotla, W. Bu, J. Zhao, S. Haricharan, Y.C. Du, K. Podsypanina, J.M. Rosen, L.A. Donehower, Y. Li, Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc. Natl. Acad. Sci. USA 107, 3728–3733 (2010)PubMedCrossRef J.P. Reddy, S. Peddibhotla, W. Bu, J. Zhao, S. Haricharan, Y.C. Du, K. Podsypanina, J.M. Rosen, L.A. Donehower, Y. Li, Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc. Natl. Acad. Sci. USA 107, 3728–3733 (2010)PubMedCrossRef
28.
go back to reference J. Bartek, J. Bartkova, J. Lukas, DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773–7779 (2007)PubMedCrossRef J. Bartek, J. Bartkova, J. Lukas, DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773–7779 (2007)PubMedCrossRef
29.
go back to reference M.B. Kastan, DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517–524 (2008)PubMedCrossRef M.B. Kastan, DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517–524 (2008)PubMedCrossRef
30.
go back to reference J.W. Harper, S.J. Elledge, The DNA damage response: ten years after. Mol. Cell. 28, 739–745 (2007)PubMedCrossRef J.W. Harper, S.J. Elledge, The DNA damage response: ten years after. Mol. Cell. 28, 739–745 (2007)PubMedCrossRef
31.
go back to reference P. Athma, R. Rappaport, M. Swift, Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92, 130–134 (1996)PubMedCrossRef P. Athma, R. Rappaport, M. Swift, Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92, 130–134 (1996)PubMedCrossRef
32.
go back to reference J. Boultwood, Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J. Clin. Pathol. 54, 512–516 (2001)PubMedCrossRef J. Boultwood, Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J. Clin. Pathol. 54, 512–516 (2001)PubMedCrossRef
33.
go back to reference M.A. Zeiger, G.B. Thompson, Q.Y. Duh, The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(1), 1–20 (2009)PubMed M.A. Zeiger, G.B. Thompson, Q.Y. Duh, The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(1), 1–20 (2009)PubMed
Metadata
Title
Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas
Authors
Junna Ye
Yan Qi
Weiqing Wang
Fukang Sun
Qin Wei
Tingwei Su
Weiwei Zhou
Yiran Jiang
Wenqi Yuan
Jianfei Cai
Bin Cui
Guang Ning
Publication date
01-06-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9593-3

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine